NAD+ 1G & RETATRUTIDE : A BRITISH REPORT

The growing interest in NAD+ supplementation, particularly at a significant dosage of 1g , continues to rise within the UK healthcare community. At the same time , attention is directed toward Retatrutide, a novel GLP-1 medication being viewed by many as a potential successor to Tirzepatide. At p